drugset / Trial / NCT04647838
Tepotinib in Solid Tumors Harboring MET Alterations
Phase 2
Unknown
100 enrolled
Chungbuk National University Hospital
Merck KGaA, Darmstadt, Germany · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to understand efficacy of tepotinib in patients with solid cancers harbouring c-MET amplification or exon 14 mutation who progressed after standard treatment for metastatic disease.
Timeline
- Start
- 2020-01-16
- Primary completion
- 2023-02-28
- Completion
- 2024-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tepotinib | Small molecule | 500 mg | Oral |